Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iclepertin Extension Safety Study in Schizophrenia-Related Cognitive Impairment
CTR20212370Phase 3Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2021
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of iclepertin in schizophrenia, sponsored by Boehringer Ingelheim. Started Sep 2021; status: terminated.
02
Drugs
iclepertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on CTR20212370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212370.